Tango Therapeutics' R&D President buys, sells shares at different prices on the same day.

Tango Therapeutics, Inc. (TNGX) has announced that Crystal Adam, President of Research and Development, has recently executed a transaction involving the acquisition and disposal of shares. Specifically, Adam purchased 12,000 shares at a price of $5.20 per share on March 25, 2026, and subsequently sold the same number of shares at a price of $20.11 per share on the same date.